Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EPS (Basic) of -$1.84 for Q1 2026, down 17.2% year-over-year from -$2.22 in Q1 2025, and down 43.75% quarter-over-quarter from -$1.28 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 14 years of EPS (Basic) data on file, last reported at -$1.84 in Q1 2026.
- EPS (Basic) for Q1 2026 came in at -$1.84, down 17.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.1 (down 3.92% YoY), and the FY2025 annual result was -$5.83, up 7.31% from the prior year.
- EPS (Basic) retreated to -$1.84 in Q1 2026 per RARE's latest filing, from -$1.28 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$1.17 in Q2 2025 and troughed at -$3.5 in Q3 2022.
- A 5-year average of -$1.9 and a median of -$1.84 in 2026 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2022 and 2024: EPS (Basic) plunged 224.07% in 2022, then surged 37.22% in 2024.
- A 5-year view of EPS (Basic) shows it stood at -$2.16 in 2022, then jumped by 33.33% to -$1.44 in 2023, then gained by 4.17% to -$1.38 in 2024, then gained by 7.25% to -$1.28 in 2025, then plunged by 43.75% to -$1.84 in 2026.
- Business Quant data shows RARE's EPS (Basic) at -$1.84 in Q1 2026, -$1.28 in Q4 2025, and -$1.81 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 0.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.06 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.06 |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -1.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.84 |
| Dec 31, 2025 | -1.28 |
| Sep 30, 2025 | -1.81 |
| Jun 30, 2025 | -1.17 |
| Mar 31, 2025 | -1.57 |
| Dec 31, 2024 | -1.38 |
| Sep 30, 2024 | -1.40 |
| Jun 30, 2024 | -1.52 |
| Mar 31, 2024 | -2.03 |
| Dec 31, 2023 | -1.44 |
| Sep 30, 2023 | -2.23 |
| Jun 30, 2023 | -2.25 |
| Mar 31, 2023 | -2.33 |
| Dec 31, 2022 | -2.16 |
| Sep 30, 2022 | -3.50 |
| Jun 30, 2022 | -2.26 |
| Mar 31, 2022 | -2.19 |
| Dec 31, 2021 | -1.79 |
| Sep 30, 2021 | -1.08 |
| Jun 30, 2021 | -1.81 |